Top Markets
Coin of the day
Ibere Pharmaceuticals Ibere Pharmaceuticals

Ibere Pharmaceuticals

IBER
Rank in Stocks #19087
Ibere Pharmaceuticals currently lacks significant operational activities, with... Ibere Pharmaceuticals currently lacks significant operational activities, with its core mission focused on executing a business combination. This could involve a merger, an acquisition of assets or shares, or a corporate restructuring with one or more other entities. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
Share Price
$10.18
Last synced: 2023-03-01
Market Cap
$175.61M
Change (1 day)
-0.29%
Change (1 year)
0.00%
Country
US
Trade Ibere Pharmaceuticals (IBER)
P/E ratio for Ibere Pharmaceuticals (IBER)
P/E ratio as of 2026 TTM: 0
According to Ibere Pharmaceuticals latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Ibere Pharmaceuticals from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.